Boston—Real-world findings from more than 200 patients treated with either recombinant FVIII Fc fusion protein (rFVIIIFc; Eloctate, Bioverativ) or rFVIII is bolstering a body of evidence showing rFVIIIFc is more effective in reducing bleeding rates in patients with severe hemophilia A.
The study, which was presented at the 2018 annual meeting of the Academy of Managed Care Pharmacy (poster D10), showed significantly lower annualized bleeding rates (ABRs) in adults treated with